Current Report Filing (8-k)
October 07 2020 - 4:52PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
October
7, 2020
AIM
IMMUNOTECH INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001
- 27072
|
|
52-0845822
|
(state
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
2117
SW Highway 484, Ocala FL
|
|
34473
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (352) 448-7797
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
AIM
|
|
NYSE
American
|
Item
5.07 Submission of Matters to a Vote of Security Holders
The
Company’s Annual Meeting of Stockholders for 2020 was held on October 7, 2020. The requisite quorum for the meeting of 40.0%
was present. At the meeting, stockholders voted as follows:
Election
of Directors:
Nominees
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
Thomas K. Equels
|
|
3,099,551.9
|
|
818,509.6
|
|
21,137,232.1
|
William M. Mitchell
|
|
3,080,232.1
|
|
837,829.5
|
|
21,137,232.0
|
Stewart L. Appelrouth
|
|
3,085,778.5
|
|
832,283.1
|
|
21,137,232.0
|
Ratification
of the selection of Morrison, Brown, Argiz & Farra, LLC as the Company’s independent accountants:
For:
22,172,240.6
|
|
Against:
1,773,067.4
|
|
Abstain:
1,109,985.5
|
Advisory,
non-binding, vote on approval of the compensation of the Company’s Named Executive Officers:
For:
2,239,872.7
|
|
Against:
1,462,457
|
|
Abstain:
215,731.9
|
|
Broker Non-Vote: 21,137,232
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AIM
ImmunoTech Inc.
|
|
|
|
October
7, 2020
|
By:
|
/s/
Thomas K. Equels
|
|
|
Thomas
K. Equels, CEO
|
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Sep 2023 to Sep 2024